Immunogenicity plays a major role in reducing anti-TNF drug levels, triggering infusion reactions, and hindering remission, particularly in Crohn’s disease, making it a critical factor in the diminished response to biologic treatments [3,5,6]. The gene discussed is TNF; the disease is Crohn disease.